Pharming (PHAR) Common Equity (2019 - 2026)

Pharming's Common Equity history runs 8 years deep, the most recent figure standing at $269.0 million for Q1 2026.

• Quarterly Common Equity rose 24.93% year-over-year to $269.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $269.0 million (up 24.93% YoY) and the FY2025 annual result came in at $277.1 million, up 25.35% from the prior year.
• Common Equity was $269.0 million for Q1 2026 at Pharming, down from $277.1 million in the prior quarter.
• Across five years, Common Equity topped out at $277.1 million in Q4 2025 and bottomed at $200254.0 in Q3 2022.
• A 5-year average of $209.8 million and a median of $215.3 million in 2025 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 104995.39% in 2022, while the deepest fall reached 99.9% in 2022.
• Pharming's Common Equity stood at $204.6 million in 2022, then rose by 6.91% to $218.8 million in 2023, then grew by 1.04% to $221.1 million in 2024, then rose by 25.35% to $277.1 million in 2025, then slipped by 2.94% to $269.0 million in 2026.
• Business Quant data shows PHAR's Common Equity at $269.0 million in Q1 2026, $277.1 million in Q4 2025, and $264.6 million in Q3 2025.